Enfusion Inc (NYSE:ENFN)
$ 8.95 0.23 (2.64%) Market Cap: 844.63 Mil Enterprise Value: 789.23 Mil PE Ratio: 223.75 PB Ratio: 11.93 GF Score: 67/100

Q2 2024 Enfusion Inc Earnings Call Transcript

Aug 06, 2024 / 12:30PM GMT
Release Date Price: $7.97 (-7.86%)

Key Points

Positve
  • Enfusion Inc (ENFN) reported a solid Q2 2024 with $49.5 million in revenue, representing a 16% year-over-year growth.
  • The company signed 39 new clients in Q2 2024, up from 33 in the previous quarter, bringing the total client count to 879.
  • Client onboarding satisfaction scores remained at three-year highs, indicating strong customer satisfaction.
  • Enfusion Inc (ENFN) achieved an adjusted EBITDA of $10.1 million, translating into a healthy adjusted EBITDA margin of 20.5%.
  • The company is expanding its market share in the institutional asset management segment, with notable client wins in the insurance and banking sectors.
Negative
  • Revenue growth rate slowed down slightly from the previous quarter, primarily due to the performance of the back book.
  • The company saw a moderation in customers' willingness to bring on additional seat and connection counts, tempering growth from the existing customer base.
  • Net Dollar Retention (NDR) was 103%, flat sequentially, impacted by lower customer upsells.
  • Geopolitical and macroeconomic headwinds in the Asia Pacific region persisted, affecting growth in that area.
  • The company faces ongoing challenges in the competitive landscape, particularly in the private market segment.
Operator

Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to Enfusion's second-quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference call is being recorded.

Now, I'd like to turn the call over to Bill Wright, Head of Investor Relations to begin.

Bill Wright
Enfusion Inc - Managing Director - Investor Relations

Good morning and thank you, operator. We welcome you to Enfusion's second-quarter 2024 earnings conference call. Hosting today's call are Oleg Movchan, Enfusion's Chief Executive Officer; Brad Herring, Enfusion's Chief Financial Officer; and Neal Pawar, Enfusion's Chief Operating Officer.

Please note our quarterly shareholder letter, which includes our quarterly financial results has been posted to our Investor Relations website.

I would like to remind you that today's call may contain forward looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including those set forth in our filings with the SEC, which are available in

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot